Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study
Open Access
- 6 October 2014
- journal article
- research article
- Published by Springer Nature in Critical Care
- Vol. 18 (5) , 534
Abstract
Introduction: Patients with distributive shock who require high dose vasopressors have a high mortality. Angiotensin II (ATII) may prove useful in patients who remain hypotensive despite catecholamine and vasopressin therapy. The appropriate dose of parenteral angiotensin II for shock is unknown. Methods: In total, 20 patients with distributive shock and a cardiovascular Sequential Organ Failure Assessment score of 4 were randomized to either ATII infusion (N =10) or placebo (N =10) plus standard of care. ATII was started at a dose of 20 ng/kg/min, and titrated for a goal of maintaining a mean arterial pressure (MAP) of 65 mmHg. The infusion (either ATII or placebo) was continued for 6 hours then titrated off. The primary endpoint was the effect of ATII on the standing dose of norepinephrine required to maintain a MAP of 65 mmHg. Results: ATII resulted in marked reduction in norepinephrine dosing in all patients. The mean hour 1 norepinephrine dose for the placebo cohort was 27.6 ± 29.3 mcg/min versus 7.4 ± 12.4 mcg/min for the ATII cohort (P =0.06). The most common adverse event attributable to ATII was hypertension, which occurred in 20% of patients receiving ATII. 30-day mortality for the ATII cohort and the placebo cohort was similar (50% versus 60%, P =1.00). Conclusion: Angiotensin II is an effective rescue vasopressor agent in patients with distributive shock requiring multiple vasopressors. The initial dose range of ATII that appears to be appropriate for patients with distributive shock is 2 to 10 ng/kg/min. Trial registration: Clinicaltrials.gov NCT01393782. Registered 12 July 2011.Keywords
This publication has 21 references indexed in Scilit:
- Angiotensin II in experimental hyperdynamic sepsisCritical Care, 2009
- Vasopressin versus Norepinephrine Infusion in Patients with Septic ShockNew England Journal of Medicine, 2008
- Review of aldosterone- and angiotensin II-induced target organ damage and preventionCardiovascular Research, 2004
- Angiotensin for septic shock unresponsive to noradrenalineArchives of Disease in Childhood, 2000
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- Enalapril overdose and the corrective effect of intravenous angiotensin II [letter]British Journal of Clinical Pharmacology, 1995
- Reversal of ‘Refractory Septic Shock’ by Infusion of Amrinone and Angiotensin II in an Anthracycline-Treated PatientChest, 1995
- Enalapril overdose treated with angiotensin infusionThe Lancet, 1993
- Administration of angiotensin II in refractory septic shockCritical Care Medicine, 1991
- Effect of a pressor infusion of angiotensin II on sympathetic activity and heart rate in normal humans.Circulation Research, 1991